From Israeli lab: First AI-designed antibody enters clinical trials

Aulos Biosciences is now recruiting cancer patients in Australian medical centers for a trial of the world's first antibody drug designed by a computer. The computationally designed antibody, known as AU-007, was planned by the artificial intelligence platform of Israeli biotech company Biolojic Design from Rehovot, in a way that would target a protein in the human body known as interleukin-2 (IL-2). The goal is for the IL-2 pathway to activate the body's immune system and attack the tumors. The clinical trial will be conducted on patients with final stage solid tumors and will last about a year – but the company hopes to present interim results during 2022. The trial has raised great hopes because if it is successful, it will pave the way for the development of a new type of drug using computational biology and "big data."